Our patents


Cantargia's strategy is to obtain an extensive patent protection for its current and future product candidates. Cantargia now has patent protection for the treatment of a number of different cancer forms using antibodies against IL1RAP. Cantargia also has a patent application pending for CAN04 and variants on this molecule, plus an application for other antibodies targeting IL1RAP. Cantargia's patent strategy is global yet at the same time focused on the markets deemed most important for the different patent families.

Karta
Patent family Patent application Approved patents Validity
Hematological cancers Australia, Europe, Israel, Japan, Canada, China, Mexico, South Africa, USA Australia, Europe (France, Italy, Netherlands, Switzerland, Spain, Great Britain, Germany), Japan, Mexico, South Africa, USA 2030
Solid tumors Australia, Brazil, Europe, Japan, Canada, China, Mexico, Russia, South Korea, USA Europe (Belgium, Denmark, France, Ireland, Italy, Netherlands, Poland, Switzerland, Spain, Sweden, Germany, Austria), Japan, USA, Russia 2032
CAN04 Australia, Brazil, Europe, India, Israel, Japan, Canada, China, Mexico, Russia, Singapore, South Africa, South Korea, USA National phase examination in progress 2035
CAN01 & CAN03 Australia, Brazil, Europe, India, Japan, Canada, China, Mexico, South Korea, USA National phase examination in progress 2035